EA202191855A1 - Соединения, содержащие расщепляемый линкер, и способы их применения - Google Patents

Соединения, содержащие расщепляемый линкер, и способы их применения

Info

Publication number
EA202191855A1
EA202191855A1 EA202191855A EA202191855A EA202191855A1 EA 202191855 A1 EA202191855 A1 EA 202191855A1 EA 202191855 A EA202191855 A EA 202191855A EA 202191855 A EA202191855 A EA 202191855A EA 202191855 A1 EA202191855 A1 EA 202191855A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
ligand
functional group
active agent
Prior art date
Application number
EA202191855A
Other languages
English (en)
Russian (ru)
Inventor
Тэкё Парк
Сун Хо У
Суньянг Ким
Сухо Парк
Дзонгун Чо
Доохван Дзунг
Донгхоон Сео
Дзаехо ЛИ
Сангкванг Ли
Сангхиеон Юн
Дзихиеон Ха
Хян Сук Ли
Окку Парк
Беомсеок Сео
Сена Ким
Мина Соль
Дзина Сонг
Original Assignee
Интоселл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интоселл, Инк. filed Critical Интоселл, Инк.
Publication of EA202191855A1 publication Critical patent/EA202191855A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA202191855A 2019-01-03 2020-01-02 Соединения, содержащие расщепляемый линкер, и способы их применения EA202191855A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962788039P 2019-01-03 2019-01-03
PCT/IB2020/000019 WO2020141460A2 (en) 2019-01-03 2020-01-02 Compounds comprising cleavable linker and uses thereof

Publications (1)

Publication Number Publication Date
EA202191855A1 true EA202191855A1 (ru) 2021-11-19

Family

ID=71407384

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191855A EA202191855A1 (ru) 2019-01-03 2020-01-02 Соединения, содержащие расщепляемый линкер, и способы их применения

Country Status (7)

Country Link
US (1) US12551570B2 (https=)
EP (1) EP3906063A4 (https=)
JP (2) JP7657153B2 (https=)
KR (1) KR20210099658A (https=)
CN (2) CN114306635A (https=)
EA (1) EA202191855A1 (https=)
WO (1) WO2020141460A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019008441A1 (en) 2017-07-04 2019-01-10 Intocell, Inc. COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF
WO2020141460A2 (en) 2019-01-03 2020-07-09 Intocell, Inc. Compounds comprising cleavable linker and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN114874287B (zh) * 2022-05-20 2024-04-02 联宁（苏州）生物制药有限公司 一种抗体偶联药物-连接子lnd1042的合成方法
WO2025252011A1 (zh) * 2024-06-03 2025-12-11 杭州多域生物技术有限公司 含Sulfoximine连接子的降解剂及其中间体和应用
CN119462688B (zh) * 2024-11-08 2026-03-10 青岛大学 一种生物素化氨基酸衍生物的制备方法
CN121494812A (zh) * 2026-01-14 2026-02-10 西南林业大学 一种基于肉桂酸衍生物的n2h4比率型荧光探针及其合成方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182232B (de) 1963-03-08 1964-11-26 Hans J Zimmer Verfahrenstechni Verfahren zur Herstellung von Trialkylaryloxysilanen
CH565791A5 (https=) 1972-07-11 1975-08-29 Sandoz Ag
US4540828A (en) 1982-06-01 1985-09-10 Vista Chemical Company Catalysts for alkoxylation reactions
JPS5978171A (ja) 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
JP3041736B2 (ja) * 1991-11-01 2000-05-15 コニカ株式会社 ハロゲン化銀写真感光材料
JP3061862B2 (ja) 1994-10-14 2000-07-10 山之内製薬株式会社 アゾール誘導体
JP2005291974A (ja) 2004-03-31 2005-10-20 Kyocera Chemical Corp フェルダジル基を有する磁性有機粒子、粒子固定方法及びマイクロアレイ
EP1867729A1 (en) 2006-06-14 2007-12-19 Libragen Water soluble phenolics derivatives with dermocosmetic and therapeutic applications
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
TWI585115B (zh) 2011-12-15 2017-06-01 普利司通股份有限公司 經穩定之多價陰離子聚合反應引發劑及其製備方法
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9499528B2 (en) 2013-04-08 2016-11-22 The University Of Akron Class of near infrared molecular probes for biological applications
CN105899539B (zh) * 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
WO2016029324A1 (en) 2014-08-29 2016-03-03 Rsem, Limited Partnership Azasulfurylpeptide-based cd36 modulators and uses thereof
US10035526B2 (en) 2014-12-03 2018-07-31 New York Air Brake, LLC Brake piston assembly
WO2016118770A1 (en) 2015-01-21 2016-07-28 The Regents Of The University Of California Affinity-assisted protein modification and recycling
CN107922375B (zh) 2015-07-30 2020-05-22 正大天晴药业集团股份有限公司 靶向idh2突变的抗肿瘤化合物及其使用方法
WO2017044043A1 (en) 2015-09-09 2017-03-16 Agency For Science, Technology And Research Process for direct amidation of amines via rh(i)-catalyzed addition of boroxines
KR101766822B1 (ko) 2015-09-10 2017-08-24 서울대학교산학협력단 디페닐설페이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 c형 간염 바이러스 관련 질환의 예방 또는 치료용 약학적 조성물
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
WO2018053552A2 (en) 2016-09-19 2018-03-22 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
WO2018124758A2 (ko) * 2016-12-28 2018-07-05 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
WO2019008441A1 (en) 2017-07-04 2019-01-10 Intocell, Inc. COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF
MX2020012718A (es) 2018-05-29 2021-02-16 Intocell Inc Derivados de benzodiazepinas novedosos y usos de los mismos.
KR20210068591A (ko) 2018-10-31 2021-06-09 주식회사 인투셀 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
WO2020141460A2 (en) 2019-01-03 2020-07-09 Intocell, Inc. Compounds comprising cleavable linker and uses thereof
EP3906064A4 (en) 2019-01-03 2023-03-08 Intocell, Inc. CLEAVABLE LINKER COMPOUNDS AND USES THEREOF

Also Published As

Publication number Publication date
JP2022515885A (ja) 2022-02-22
JP7657153B2 (ja) 2025-04-04
CN113423431A (zh) 2021-09-21
KR20210099658A (ko) 2021-08-12
WO2020141460A3 (en) 2020-08-27
CN114306635A (zh) 2022-04-12
US12551570B2 (en) 2026-02-17
EP3906063A2 (en) 2021-11-10
WO2020141460A2 (en) 2020-07-09
JP2025020144A (ja) 2025-02-12
EP3906063A4 (en) 2023-03-01
US20210393795A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
EA202191855A1 (ru) Соединения, содержащие расщепляемый линкер, и способы их применения
EA202191854A1 (ru) Соединения, содержащие расщепляемый линкер, и способы их применения
MX2019015940A (es) Compuestos que comprenden un enlazador escindible y sus usos.
Zheng et al. Lysine-targeted reversible covalent ligand discovery for proteins via phage display
Mamidyala et al. In situ click chemistry: probing the binding landscapes of biological molecules
England et al. NanoLuc: a small luciferase is brightening up the field of bioluminescence
Ekkebus et al. On terminal alkynes that can react with active-site cysteine nucleophiles in proteases
Forster et al. Development, optimization, and structure–activity relationships of covalent-reversible JAK3 inhibitors based on a tricyclic Imidazo [5, 4-d] pyrrolo [2, 3-b] pyridine scaffold
Voss et al. Risk1, a phosphatidylinositol 3-kinase effector, promotes Rickettsia typhi intracellular survival
Chouhan et al. Efficient construction of proline-containing β-Turn mimetic cyclic tetrapeptides via CuAAC macrocyclization
Liu et al. Selective class I HDAC inhibitors based on aryl ketone zinc binding induce HIV-1 protein for clearance
Kulkarni et al. Chemoproteomics of an indole-based quinone epoxide identifies druggable vulnerabilities in vancomycin-resistant Staphylococcus aureus
Huang et al. Design, synthesis, and evaluation of trivalent PROTACs having a functionalization site with controlled orientation
US20140179543A1 (en) Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction
JP2013146275A (ja) マイコバクテリウム属の疾患検出、処置、および薬物開発
Murphy-Benenato et al. Synthesis, structure, and SAR of tetrahydropyran-based LpxC inhibitors
Ojo et al. Nrf2-Keap1 Activation, A Promising Strategy in the Prevention of Cancer.
Varshney et al. A trans-translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis
Højfeldt et al. Transforming ligands into transcriptional regulators: building blocks for bifunctional molecules
AU2013254904A1 (en) Mycobacterial disease detection, treatment, and drug discovery
Bagchi et al. Crosstalk between cyclic-di-guanosine monophosphate and the sensor kinase MtrB regulates MtrA-dependent genes, bacterial growth, biofilm formation and lysosomal trafficking of Mycobacterium tuberculosis
Bertrand et al. Mild and Selective Mono-Iodination of Unprotected Peptides as Initial Step for the Synthesis of Bioimaging Probes
Balganesh et al. Drug discovery for tuberculosis: Bottlenecks and path forward
AU2007220008B2 (en) Mycobacterial disease detection, treatment, and drug discovery
Karlsson et al. A generic strategy for pharmacological caging of growth factors for tissue engineering